Skip to main content

Table 4 The univariate and multivariate analyses of the prognostic factors for survival

From: Prognostic significance of the total number of harvested lymph nodes for lymph node-negative gastric cancer patients

 

Univariate HR (95% CI)

P-value

Multivariate HR (95% CI)

P-value

Sex

 

0.138

  

 Male

1

   

 Female

1.462 (0.883, 2.421)

   

BMI

 

0.437

  

 <19

1

   

 ~ < 25

0.901 (0.383, 2.116)

   

 ~ < 30

0.671 (0.258, 1.745)

   

 ≥30

0.891 (0.128, 1985)

   

Differentiation

 

0.284

  

 Well

1

   

 Moderate

2.063 (0.495, 8.587)

   

 Poor

2.669 (0.637, 11.188)

   

LVI

 

0.659

  

 No

1

   

 Yes

1.336 (0.681, 2.622)

   

Postoperative hospital stay

1.004 (0.996, 1.013)

0.335

  

Reoperation

 

0.247

  

 No

1

   

 Yes

1.959 (0.614, 6.246)

   

Tumour size

 

0.013

 

0.643

 ≤5 cm

1

 

1

 

 >5 cm

2.088 (1.151, 3.789)

 

1.174 (0.596, 2.314)

 

Gastrectomy

 

<0.001

 

0.707

 Distal

1

 

1

 

 Proximal

2.565 (1.392, 4.728)

 

1.267 (0.649, 2.473)

 

 Total

2.746 (1.555, 4.848)

 

1.267 (0.665, 2.413)

 

 Blood loss volume

1.001 (1.001, 1.002)

0.001

1.001 (0.999, 1.002)

0.296

Complication

 

0.013

 

0.332

 No

1

 

1

 

 Yes

2.122 (1.157, 3.890)

 

1.387 (0.716, 2.686)

 

Age

 

0.009

 

0.031

 ≤60

1

 

1

 

 >60

1.918 (1.169, 3.148)

 

1.830 (1.058, 3.165)

 

NACT

 

0.002

 

0.093

 No

1

 

1

 

 Yes

2.133 (1.310, 3.473)

 

1.600 (0.924, 2.771)

 

T stagea

 

<0.001

 

<0.001

 T1

1

 

1

 

 T2

4.126 (1.486, 11.461)

 

3.930 (1.378, 11.209)

 

 T3

6.065 (2.463, 16.435)

 

5.089 (2.456, 15.364)

 

 T4

8.092 (3.211, 20.391)

 

7.946 (3.065, 20.691)

 

Operation duration

1.006 (1.003, 1.008)

<0.001

1.007 (1.004, 1.010)

<0.001

Total number of HLNs

 

0.047

 

0.002

N < 22

1

 

1

 

N ≥ 22

0.618 (0.383, 0.999)

 

0.437 (0.262, 0.730)

 
  1. HLNs harvested lymph nodes, HR hazard ratio, CI confidence interval, BMI body mass index, LVI lymphovascular invasion, NACT neoadjuvant chemotherapy
  2. a7th AJCC TNM staging system for gastric cancer